Literature DB >> 9012464

Identification of three distinct tumor suppressor loci on the short arm of chromosome 9 in small cell lung cancer.

S K Kim1, J Y Ro, B L Kemp, J S Lee, T J Kwon, K M Fong, Y Sekido, J D Minna, W K Hong, L Mao.   

Abstract

Deletion at 9p21 is frequent in many tumor types. A candidate tumor suppressor gene, p16INK4a, was mapped to this region and is frequently inactivated by several different mechanisms in many tumor types, including non-small cell lung cancer, but not in small cell lung cancer (SCLC). p16 functions as a cyclin/CDK inhibitor to prevent phosphorylation of pRB. It has been demonstrated that most SCLCs have lost pRB but retained p16, and the inactivation of pRB excludes the inactivation of p16 and vice versa. To determine the potential existence of other tumor suppressor genes on the short arm of chromosome 9 in SCLC, we tested 46 primary SCLCs by microsatellite analysis. We found that more than 89% of the tumors exhibited loss of heterozygosity (LOH) at 9p with three distinct minimal deleted areas. Among those areas, LOH at 9p21 was most frequent (86%), with a peak at a marker 150 kb telomeric to p16INK4a. LOH was also observed in more than 50% of the tumors at two other regions, 9p22 and 9p13. Our data strongly suggest the presence of at least three novel tumor suppressor loci on 9p in SCLC, and further investigations to clone candidate tumor suppressor genes are warranted.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9012464

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  12 in total

1.  The human XRCC9 gene corrects chromosomal instability and mutagen sensitivities in CHO UV40 cells.

Authors:  N Liu; J E Lamerdin; J D Tucker; Z Q Zhou; C A Walter; J S Albala; D B Busch; L H Thompson
Journal:  Proc Natl Acad Sci U S A       Date:  1997-08-19       Impact factor: 11.205

2.  Nasopharyngeal carcinomas frequently lack the p16/MTS1 tumor suppressor protein but consistently express the retinoblastoma gene product.

Authors:  M L Gulley; J M Nicholls; B G Schneider; M B Amin; J Y Ro; J Geradts
Journal:  Am J Pathol       Date:  1998-04       Impact factor: 4.307

3.  Mutational inactivation of PTPRD in glioblastoma multiforme and malignant melanoma.

Authors:  David A Solomon; Jung-Sik Kim; Julia C Cronin; Zita Sibenaller; Timothy Ryken; Steven A Rosenberg; Habtom Ressom; Walter Jean; Darell Bigner; Hai Yan; Yardena Samuels; Todd Waldman
Journal:  Cancer Res       Date:  2008-12-15       Impact factor: 12.701

4.  Loss of heterozygosity and methylation of p16 in renal cell carcinoma.

Authors:  M T Sanz-Casla; M L Maestro; V del Barco; I Zanna; J Moreno; M Vidaurreta; I Almansa; C Fernández; J Blanco; C Maestro; L Resel
Journal:  Urol Res       Date:  2003-03-25

5.  Differential expression of Fmr-1 mRNA and FMRP in female mice brain during aging.

Authors:  Kanchan Singh; S Prasad
Journal:  Mol Biol Rep       Date:  2007-09-27       Impact factor: 2.316

6.  Evaluation of loss of heterozygosity and microsatellite instability in human pterygium: clinical correlations.

Authors:  E T Detorakis; G Sourvinos; J Tsamparlakis; D A Spandidos
Journal:  Br J Ophthalmol       Date:  1998-11       Impact factor: 4.638

7.  Age- and sex-dependent differential interaction of nuclear trans-acting factors with Fmr-1 promoter in mice brain.

Authors:  S Prasad; Kanchan Singh
Journal:  Neurochem Res       Date:  2007-12-14       Impact factor: 3.996

8.  RNF38 encodes a nuclear ubiquitin protein ligase that modifies p53.

Authors:  Jamie E Sheren; C Kenneth Kassenbrock
Journal:  Biochem Biophys Res Commun       Date:  2013-08-22       Impact factor: 3.575

9.  High prevalence of p16 genetic alterations in head and neck tumours.

Authors:  E C Miracca; L P Kowalski; M A Nagai
Journal:  Br J Cancer       Date:  1999-10       Impact factor: 7.640

10.  The prognostic significance of allelic imbalance at key chromosomal loci in oral cancer.

Authors:  M Partridge; G Emilion; S Pateromichelakis; R A'Hern; G Lee; E Phillips; J Langdon
Journal:  Br J Cancer       Date:  1999-04       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.